Sandoz Gets FDA Approval for Humira Biosimilar
The company received FDA approval for Hyrimoz (adalimumab-adaz), its biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).
On Oct. 31, 2018, Sandoz, a Novartis division, announced that it received FDA approval for its biosimilar, Hyrimoz (adalimumab-adaz), which references AbbVie’s blockbuster Humira (adalimumab). Humira is AbbVie’s top-selling product with $18.4 billion in 2017 sales.
FDA granted Hyrimoz approval to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC) and plaque psoriasis (Ps).
"Biosimilars can help people suffering from chronic, debilitating conditions gain expanded access to important medicines that may change the outcome of their disease," said Stefan Hendriks, global head of biopharmaceuticals, Sandoz, in a company press release. "With [FDA] approval of Hyrimoz, Sandoz is one step closer to offering US patients with autoimmune diseases the same critical access already available in Europe."
Hyrimoz is Sandoz's third approved biosimilar medicine in the United States. Additional biosimilars for oncology and immunology indications are expected to launch globally across major regions by 2020.
On Oct. 11, 2018, Sandoz announced a global resolution of all intellectual property-related litigation with AbbVie concerning all indications of the proposed Sandoz biosimilar adalimumab for the reference medicine. The license enables patient access in the US to Hyrimoz (or Sandoz adalimumab or Sandoz biosimilar) as of September 30, 2023. Hyrimoz is a trademark of Novartis.
Source: Novartis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
